Midatech Pharma PLC
www.midatechpharma.com
Latest From Midatech Pharma PLC
New CEO of Renamed Spin-Out Fortovia Therapeutics Will Be ‘Solely US-Focused’
Newly installed Fortovia Therapeutics CEO Peter Melnyk tells Scrip his arrival and the company’s name change from Midatech Pharma US signals a strategic revamp for the privately held spin-out.
Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Embattled Midatech Receives Lifeline From China To Save Cancer Candidate
A Chinese billionaire has invested in UK biotech Midatech and signed a licensing deal for an as yet unapproved carcinoid cancer drug, sending it much-needed backing just days after the company said it did not have enough cash to get it to the second half of the year.
UK's Midatech Makes Desperate Cash Call
The Oxford-based biotech needs more money and fast to fund development of MTD201, which it believes offers a number of competitive advantages over Novartis blockbuster Sandostatin LAR.
Company Information
- Industry
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Site Specific
- Specialty Pharmaceuticals
-
Drug Delivery
- Therapeutic Areas
- Cancer
- Immune Disorders
- Metabolic Disorders
- Neurology, Nervous System
- Ophthalmic
- Alias(es)
- Midatech Ltd.
- Ownership
- Public
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
UK
-
UK
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Midatech Pharma PLC
- Senior Management
-
Craig Cook, MD, CEO
Nick Robbins-Cherry, CFO
Steve Damment, PhD, Head, R&D
Rob Rainey, Head, Corp. Dev. - Contact Info
-
Midatech Pharma PLC
Phone: 1235 841 575
65 Innovation Dr.
Milton Pk
Abingdon, OX14 4RQ
UK